M. Azuma

Immunology · 2002–2012

A researcher in the Science corpus: 9 papers; trusts 2 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

• Immunology — 116 citations into it; #1,164 of 2,160 by trust here, #530 by citations
• Oncology — 70 citations into it; #1,514 of 1,698 by trust here, #431 by citations

Whom M. Azuma trusts

Their strongest outbound trust, strongest first, inferred from their citations.

1. G. Freeman (in Immunology)
2. Arlene H. Sharpe (in Immunology)

Who trusts M. Azuma

1. D. Pardoll (in Immunology)
2. Lieping Chen (in Immunology)
3. Arlene H. Sharpe (in Immunology)

Papers from M. Azuma's perspective

Ordered by how strongly the researchers M. Azuma trusts endorse each paper. Same corpus, a different order for every researcher.

1. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade (Proceedings of the National Academy of Sciences of the United States of America)
2. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (Nature Medicine)
3. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection (Nature Immunology)
4. PD‐1:PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2 (European Journal of Immunology)
5. The PD-1-PD-L pathway in immunological tolerance. (Trends in immunology)
6. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression (Nature)
7. PD-1 and its ligands in tolerance and immunity. (Annual Review of Immunology)
8. The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice (Journal of Experimental Medicine)
9. Cutting Edge: IL-2 Is Critically Required for the In Vitro Activation of CD4+CD25+ T Cell Suppressor Function (Journal of Immunology)
10. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase (Nature Medicine)

Their papers

• Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 (2012) — 1,074 citations
• Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. (2011) — 659 citations
• Interactions between programmed death-1 and programmed death ligand-1 promote tolerance by blocking the T cell receptor-induced stop signal (2009) — 653 citations
• Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. (2007) — 804 citations
• Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer (2007) — 869 citations
• Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer (2005) — 770 citations
• B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression (2004) — 729 citations
• The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice (2003) — 839 citations
• Expression of Programmed Death 1 Ligands by Murine T Cells and APC1 (2002) — 825 citations